Virtus Biotech Clinical Trials ETF
BBC
17 hedge funds and large institutions have $7.99M invested in Virtus Biotech Clinical Trials ETF in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
51% more capital invested
Capital invested by funds: $5.28M → $7.99M (+$2.71M)
6% more funds holding
Funds holding: 16 → 17 (+1)
6.09% more ownership
Funds ownership: 30.21% → 36.3% (+6.1%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$283K |
| 2 |
LPL Financial
San Diego,
California
|
+$264K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$209K |
| 4 |
Jane Street
New York
|
+$100K |
| 5 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$51.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$426K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$334K |
| 3 |
SG Americas Securities
New York
|
-$88.8K |
| 4 |
Goldman Sachs
New York
|
-$47.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$20.9K |
BBC Hedge Fund Activity: Q1 2017 in Review
17 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2017, worth a combined $7.99M — up 51% from $5.28M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBC positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $283K. The largest seller was Citadel Advisors, exiting entirely with an estimated $426K sold.
- 17 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2017, up from 16 in Q4 2016.
- Funds reported $7.99M of Virtus Biotech Clinical Trials ETF stock for Q1 2017, up 51% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2017 and 1 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2017 was Virtu KCG Holdings, an estimated $283K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2017 was Citadel Advisors, an estimated $426K sold.
Based on aggregated 13F filings for Q1 2017.